The PPAR α/γ Agonist Saroglitazar Improves Insulin Resistance and Steatohepatitis in a Diet Induced Animal Model of Nonalcoholic Fatty Liver Disease
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
The PPAR α/γ Agonist Saroglitazar Improves Insulin Resistance and Steatohepatitis in a Diet Induced Animal Model of Nonalcoholic Fatty Liver Disease
Authors
Keywords
-
Journal
Scientific Reports
Volume 10, Issue 1, Pages -
Publisher
Springer Science and Business Media LLC
Online
2020-06-09
DOI
10.1038/s41598-020-66458-z
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- The Role of Nrf2 in Liver Disease: Novel Molecular Mechanisms and Therapeutic Approaches
- (2019) Dongwei Xu et al. Frontiers in Pharmacology
- Ultrahigh-Throughput Multiplexing and Sequencing of >500-Base-Pair Amplicon Regions on the Illumina HiSeq 2500 Platform
- (2019) Johanna B. Holm et al. mSystems
- Sex Differences in NAFLD : State of the Art and Identification of Research Gaps
- (2019) Amedeo Lonardo et al. HEPATOLOGY
- Update in the classification and the role of intra-arterial stenting in the management of carotid body paragangliomas
- (2019) Sampath Chandra Prasad et al. HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK
- Sex differences in metabolic regulation and diabetes susceptibility
- (2019) Blandine Tramunt et al. DIABETOLOGIA
- Endoplasmic Reticulum stress signaling and the pathogenesis of Non-Alcoholic Fatty Liver Disease
- (2018) Cynthia Lebeaupin et al. JOURNAL OF HEPATOLOGY
- Mechanisms of NAFLD development and therapeutic strategies
- (2018) Scott L. Friedman et al. NATURE MEDICINE
- IL-1 Family Cytokine Pathways Underlying NAFLD: Towards New Treatment Strategies
- (2018) Andreea-Manuela Mirea et al. TRENDS IN MOLECULAR MEDICINE
- Non-coding RNAs in Various Stages of Liver Disease Leading to Hepatocellular Carcinoma: Differential Expression of miRNAs, piRNAs, lncRNAs, circRNAs, and sno/mt-RNAs
- (2018) Srinivas V. Koduru et al. Scientific Reports
- Complete Resolution of Nonalcoholic Fatty Liver Disease After Bariatric Surgery: A Systematic Review and Meta-Analysis
- (2018) Yung Lee et al. Clinical Gastroenterology and Hepatology
- Targeting Metabolism, Insulin Resistance, and Diabetes to Treat Nonalcoholic Steatohepatitis
- (2018) Brian N. Finck DIABETES
- A Novel Regulatory Role of Apoptosis Antagonizing Transcription Factor in the Pathogenesis of NAFLD and HCC
- (2018) Divya P. Kumar et al. HEPATOLOGY
- Metabolomic Identification of Subtypes of Nonalcoholic Steatohepatitis
- (2017) Cristina Alonso et al. GASTROENTEROLOGY
- Pioglitazone for the treatment of NASH in patients with prediabetes or type 2 diabetes mellitus
- (2017) Kenneth Cusi GUT
- Modeling the epidemic of nonalcoholic fatty liver disease demonstrates an exponential increase in burden of disease
- (2017) Chris Estes et al. HEPATOLOGY
- Nrf2, the Master Regulator of Anti-Oxidative Responses
- (2017) Sandra Vomund et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Dual PPARα/γ agonist saroglitazar improves liver histopathology and biochemistry in experimental NASH models
- (2017) Mukul R. Jain et al. LIVER INTERNATIONAL
- The Transcriptomic Signature Of Disease Development And Progression Of Nonalcoholic Fatty Liver Disease
- (2017) Sophie Cazanave et al. Scientific Reports
- Pemafibrate, a novel selective peroxisome proliferator-activated receptor alpha modulator, improves the pathogenesis in a rodent model of nonalcoholic steatohepatitis
- (2017) Yasushi Honda et al. Scientific Reports
- A diet-induced animal model of non-alcoholic fatty liver disease and hepatocellular cancer
- (2016) Amon Asgharpour et al. JOURNAL OF HEPATOLOGY
- NAFLD and liver transplantation: Current burden and expected challenges
- (2016) Raluca Pais et al. JOURNAL OF HEPATOLOGY
- Molecular mechanisms of lipotoxicity and glucotoxicity in nonalcoholic fatty liver disease
- (2016) Manoela Mota et al. METABOLISM-CLINICAL AND EXPERIMENTAL
- HPV status is associated with altered PIWI-interacting RNA expression pattern in head and neck cancer
- (2016) Natalie Firmino et al. ORAL ONCOLOGY
- Nonalcoholic fatty liver disease
- (2015) Timothy Hardy et al. CURRENT OPINION IN GASTROENTEROLOGY
- Saroglitazar for the treatment of dyslipidemia in diabetic patients
- (2015) Shashank R Joshi EXPERT OPINION ON PHARMACOTHERAPY
- Nonalcoholic Fatty Liver Disease
- (2015) Mary E. Rinella JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Enhancing metabolomics research through data mining
- (2015) Ibon Martínez-Arranz et al. Journal of Proteomics
- Stabilization of LKB1 and Akt by neddylation regulates energy metabolism in liver cancer
- (2015) Lucía Barbier-Torres et al. Oncotarget
- The effect of pioglitazone on weight, lipid profile and liver enzymes in type 2 diabetic patients
- (2015) Nasser Aghamohammadzadeh et al. Therapeutic Advances in Endocrinology and Metabolism
- Saroglitazar for the treatment of hypertriglyceridemia in patients with type 2 diabetes: current evidence
- (2015) Sosale Aravind Sosale et al. Diabetes Metabolic Syndrome and Obesity-Targets and Therapy
- Selective peroxisome proliferator-activated receptorα modulators (SPPARMα): The next generation of peroxisome proliferator-activated receptor α-agonists
- (2013) Jean-Charles Fruchart Cardiovascular Diabetology
- Pharmacokinetics, Safety, and Tolerability of Saroglitazar (ZYH1), a Predominantly PPARα Agonist with Moderate PPARγ Agonist Activity in Healthy Human Subjects
- (2013) Rajendra H. Jani et al. CLINICAL DRUG INVESTIGATION
- Pathophysiology of NASH: Perspectives for a Targeted Treatment
- (2013) Fabio Marra et al. CURRENT PHARMACEUTICAL DESIGN
- A Multicenter, Prospective, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of Saroglitazar 2 and 4 mg Compared with Placebo in Type 2 Diabetes Mellitus Patients Having Hypertriglyceridemia Not Controlled with Atorvastatin Therapy (PRESS VI)
- (2013) Rajendrakumar H. Jani et al. Diabetes Technology & Therapeutics
- The global NAFLD epidemic
- (2013) Rohit Loomba et al. Nature Reviews Gastroenterology & Hepatology
- NAFLD, NASH and liver cancer
- (2013) Gregory A. Michelotti et al. Nature Reviews Gastroenterology & Hepatology
- Obesity-Dependent Metabolic Signatures Associated with Nonalcoholic Fatty Liver Disease Progression
- (2012) J. Barr et al. JOURNAL OF PROTEOME RESEARCH
- Liver Fibrogenesis in Non-Alcoholic Steatohepatitis
- (2012) Zhaolian Bian et al. Frontiers in Physiology
- Meta-analysis: pioglitazone improves liver histology and fibrosis in patients with non-alcoholic steatohepatitis
- (2011) E. Boettcher et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- Pioglitazone, Vitamin E, or Placebo for Nonalcoholic Steatohepatitis
- (2010) Arun J. Sanyal et al. NEW ENGLAND JOURNAL OF MEDICINE
- Lipotoxicity in nonalcoholic fatty liver disease: not all lipids are created equal
- (2009) Naim Alkhouri et al. Expert Review of Gastroenterology & Hepatology
- A pilot trial of fenofibrate for the treatment of non-alcoholic fatty liver disease
- (2008) C. Fernández-Miranda et al. DIGESTIVE AND LIVER DISEASE
- Activation and Dysregulation of the Unfolded Protein Response in Nonalcoholic Fatty Liver Disease
- (2007) Puneet Puri et al. GASTROENTEROLOGY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search